Eli Lilly shares rise after EU panel backs expanded use of Jaypirca
Eli Lilly shares rise after EU panel backs expanded use of Jaypirca Proactive uses images sourced from Shutterstock…
Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously…
European health chief says EU is at ‘a critical point’ in ensuring new drug access
By Maggie Fick BARCELONA, April 22 (Reuters) – Europe is at a critical juncture for ensuring future access…
Milestone announces acceptance of MAA by EMA for etripamil nasal spray
Milestone Pharmaceuticals (MIST) announced the acceptance of a Marketing Authorization Application, MAA, by the European Medicines Agency, EMA,…
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
REDWOOD CITY, Calif., December 31, 2025–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery…
High-Dose Wegovy Takes Aim at Lilly’s Zepbound
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) said its high-dose version of Wegovy has received a…
Hair-loss drug boosts hair growth by 539% – Irish study
After decades of limited options for male-pattern baldness, a new topical drug has delivered encouraging results in late-stage…